Key Takeaways
- Domestic formulation leads, exports drag: India formulations grew 11%, beating the market, while branded ROW exports fell 18% and institutional antimalarial collapsed 70%, pulling overall revenue lower.
- Unichem turnaround is the central story: Revenue grew 43.6% and EBITDA margin swung from negative 14.1% to positive 8.8%, with a clear path to INR2,000 crores revenue and 15% margin by FY26.
- Margin recovery is underway but gradual: Standalone EBITDA margin improved 278 bps to 18.55%, driven by material cost relief and stable procurement prices; Unichem's full margin journey will take 1 to 1.5 years due to regulatory timelines.
- US re-entry is a multi-year unlock, not a near-term boost: 7 products may ship in early Q1 FY25, with 15 to 17 launches over 2 years, but management declined to quantify revenue, noting "nobody is waiting for your product."
- What to watch next quarter: Whether the 7 US products actually begin shipping, the pace of Unichem's margin expansion toward the 15% target, and whether branded ROW stabilizes after the CIS and Myanmar disruptions.
Unichem Turnaround
- Revenue acceleration: Total income grew 43.6% in Q3, driven by operational changes, improved productivity, substantially improved production capacity, and commercialization of new formulations that received approval in the past.
- Profitability inflection: EBITDA margin swung from negative 14.1% in Q3 FY23 to positive 8.8% in Q3 FY24, with PBT of around INR16 crores before exceptional income from the sale of residual Optimus shares.
- The margin journey is regulatory-gated: Process corrections require regulatory filing, approval, stability studies, and further filings before revised processes become effective in formulations. This cannot happen in 3 to 6 months; it takes 1 to 1.5 years. Current improvements come from operations, overhead, cost side, productivity and business improvement.
- Bayshore integration: Bayshore, originally set up to market IPCA products, will merge with Unichem since Unichem will now handle marketing. Team synchronization is underway and will bring certain costs down.
- Goa plant validation: Validation of processes for bigger products at Unichem's Goa plants is ongoing, which could bring further improvement once approved.
Ajit Kumar Jain: "It's a journey, it cannot happen in over a period of 3 to 6 months time. It take a long time. So maybe 1 year, 1.5 years and all"
US Market Re-entry
- Supply restart timeline: For the 7 products being worked on, procedural aspects take around 12 months, but since work is already underway, shipment may start in the early part of Q1 FY25.
- Product pipeline: Around 15 to 17 products can be launched over a period of 2 years, drawn from a basket of around 40 products at various stages: some post-approval, some pre-approval, some needing site changes or new processes. Most of the review has already happened; approvals can come in a phased manner.
- API business restart: IPCA completely stopped API shipments to US formulators in the last 10 years. Discussions have restarted to regain that business, but it is time-consuming because processes have changed and parties need updated sampling and approvals.
- No revenue guidance: Management declined to quantify US revenue, noting that even with cost competency, products must be relaunched one by one and market share built gradually.
Harish Kamath: "It is too early to give any guidance. See, nobody is waiting for your product. Even though I have cost competency, I will have to again relaunch product one by one and go on taking market share."
Domestic Formulation
- Market-beating growth: Domestic formulation delivered 11% growth for the quarter, outperforming the market in both acute and chronic therapies.
- Growth composition: India growth of 13% to 14% comprises around 4% to 5% price increase and the rest volume. Growth was slightly below expectation due to unfavorable seasonality in the quarter.
- MR productivity: Productivity improved by around INR20,000 per man in the current year, though Q3 seasonality meant sales were a bit lower than expected.
- Field force expansion: Additional field force increase will be not more than 5% of overall field force size going forward.
Export & API Headwinds
- Branded ROW decline: Exports fell from INR128 crores to INR105 crores, driven by three discrete issues: certain shipments not going to the CIS market, Myanmar import licenses getting delayed for a long period, and West Africa affected by both the Red Sea issue and market slowness.
- Institutional antimalarial collapse: Revenue dropped from INR277 crores to INR83 crores, a 70% decline that was the single largest drag on the quarter.
- API business stabilization: API revenue declined from INR329 crores to around INR285 crores, with continued volume decline in certain APIs, but pricing is now getting stabilized. Sartans saw significant price reduction earlier, but prices have stabilized. For products being transferred from Ratlam to Dewas, price stability is there.
- API outlook: Both API and ROW branded business should give reasonable growth in the next financial year; API business should stabilize and grow going forward.
Generic Business & Subsidiaries
- Generic business momentum: The last 3 quarters have delivered similar growth on a continuous basis. UK business grew about 100% in the first 9 months, European generic business did very well, and South Africa grew 12% in the first 9 months despite expectations of INR40-50 crores in losses.
- Conservative growth guide: On a conservative basis, management guided 12% to 15% growth for the generic business going forward, with whatever comes out of the US added on top.
- Lyka performance: Business growth is good despite a plant shutdown for upgradations. Renovation will complete in Q1 of the current year, followed by validations and filings for developed markets. Lyka added around 100 people for direct marketing of injectables, which is giving good results, and can add more people next financial year.
- Krebs progress: Losses are reducing; product validations are ongoing; some intermediate products are getting approved in dossiers, which will help use capacities, but it will take time until approvals come.
- Dewas plant: Around 7 to 8 product commercialization projects are ongoing; some products already filed with European authorities; one product approval recently came. It may take around 6 months for at least 5 to 6 products to get approved, after which regular shipments can start.
- Nagpur plant: Consent to operate has just been received; planning is underway for captive consumption of one intermediate, which will only reduce cost with no top-line impact.
Margins & Costs
- Standalone margin improvement: EBITDA margin improved by around 278 bps to 18.55%, driven by a 265 bps improvement in the material cost to sales ratio over the first 9 months. Shipping costs and energy costs moderated versus December 2022, and price stability is being witnessed on the majority of procurement.
- Consolidated margin: EBITDA margin improved 112 bps to 16.12%, with material costs to operational income improving 239 bps to 33.95%.
- Personnel costs: Growing around 12%, which includes around 7% to 8% normal increments and added field force; manufacturing and other expenses saw hardly any increase.
- Elenium impact: Hardly any advantage, only 1% to 2%, because while there was a price rise, there was a similar reduction a few months back due to readjustment of prices.
- Sequential margin question unanswered: When asked about the sequential 300 bps impact on IPCA's base business after adjusting for Unichem, management did not address the sequential question, instead discussing year-on-year material cost improvement.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Unichem revenue and margin target | INR2,000 crores revenue, 15% EBITDA margin (INR300 crores EBITDA) | By FY26 |
| Unichem margin journey | Margin improvement will continue; full process-to-formulation cycle takes regulatory approvals | 1 to 1.5 years |
| US product shipments begin | 7 products being worked on; shipment may start early part of Q1 | Early Q1 FY25 |
| US product launches | 15 to 17 products can be launched from a basket of ~40 | Over 2 years |
| Dewas plant commercialization | 5 to 6 products to get approved, then regular shipments start | ~6 months |
| Overall company growth | Continuously growing around 10% to 12% | From next year onwards |
| Generic business growth | 12% to 15% growth on a conservative basis, plus any US business | Going forward |
| Branded ROW growth | Around 10% growth despite difficulties | Next financial year |
| Field force expansion | Not more than 5% increase in overall field force size | Going forward |
| India formulation growth | 13% to 14% growth, with 4% to 5% price and rest volume | Ongoing |
Key Metrics
| Metric | Q3 FY24 |
|---|---|
| Domestic formulation revenue growth | 11% for the quarter |
| Export formulation revenue | ₹433 cr, +8% YoY from ₹400 cr |
| Export generic business (UK & other) revenue | ₹252 cr, +33% YoY from ₹189 cr |
| API business revenue | ₹285 cr, declined from ₹329 cr in Q3 FY23 |
| Branded formulation (ROW) revenue | ₹105 cr, declined from ₹128 cr in Q3 FY23 |
| Institutional antimalarial revenue | ₹83 cr, declined from ₹277 cr in Q3 FY23 |
| Standalone EBITDA margin | 18.55%, improved 2.78 ppt from 15.77% in Q3 FY23 |
| Consolidated EBITDA margin (before exchange/exceptional) | 16.12%, up 1.12 ppt from 15% in Q3 FY23 |
| Material cost to sales ratio (standalone) | 32.21%, improved from 34.86% in Q3 FY23 |
| Unichem revenue growth | 43.6% for the quarter |
| Unichem EBITDA margin | 8.8%, improved from negative 14.1% in Q3 FY23 |
| Unichem PBT (before exceptional income) | ~₹16 cr |
| Domestic chronic segment growth (IQVIA MAT Dec '23) | ~15.9% vs market growth of 11% |
| Domestic acute segment growth (IQVIA MAT Dec '23) | ~11.3% vs market growth of 9.1% |
| MR productivity | ~₹4,25,000 per month |
| Medical rep count | ~7,000 |
| US products expected for launch in next 12 months | 8 to 9 products |
| US products expected for launch over 2 years | 15 to 17 products |
| Generic business forward growth guidance | 12% to 15% (conservative) |
| Unichem FY26 guidance | ₹2,000 cr revenue, 15% EBITDA margin |